Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 30

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 30
---
 right to vote at the Special Meeting but will transfer the right to receive the Merger Consideration to the person to whom 
 you transfer your shares. In order to receive the Merger Consideration, you must hold your shares upon completion of the Transactions.                                                            |

| Q: | Do Enfusion Stockholders have appraisal rights? |

| A: | Yes. Enfusion Stockholders are entitled to appraisal rights under Section 262 of the Delaware General                                                                                                                            
 Corporation Law (the “DGCL”) in connection with the Merger provided they follow the procedures and satisfy the conditions set forth in Section 262 of the DGCL. For more information regarding appraisal rights, see the section 
 titled “Appraisal Rights of Enfusion Stockholders.” In addition, a copy of Section 262 of the DGCL is attached as Annex E to this Proxy Statement/Prospectus. Failure to strictly comply with Section 262 of the DGCL may        
 result in your waiver of, or inability to, exercise appraisal rights.                                                                                                                                                            |

| Q: | Who will solicit and pay the cost of soliciting proxies? |

| A: | Enfusion will pay for the proxy solicitation costs related to the Special Meeting. Enfusion has engaged                                                                                                                                              
 Innisfree to assist in the solicitation of proxies for the Special Meeting. Enfusion estimates that it will pay Innisfree a fee of approximately $20,000, plus reasonable                                                                            
 out-of-pocket expenses. Enfusion will also reimburse banks, brokerage firms, custodians, trustees, nominees and fiduciaries who hold shares for the benefit of another                                                                               
 party for their expenses incurred in sending proxies and proxy materials to beneficial owners of Enfusion Common Stock. Enfusion’s directors, officers and employees also may solicit proxies in person by telephone or over the Internet. They will 
 not be paid any additional amounts for soliciting proxies.                                                                                                                                                                                           |

| Q: | How can I find more information about Clearwater and Enfusion? |

| A: | You can find more information about Clearwater and Enfusion from various sources described in the section 
 titled “Where You Can Find More Information.”                                                             |

| Q: | Who can answer any questions I may have about the Special Meeting or the proxy materials? |

| A: | If you have any questions about the Special Meeting, the Transactions, the proposals or this Proxy                                                                                                                                                      
 Statement/Prospectus, would like additional copies of the Proxy Statement/Prospectus, need to obtain proxy cards or other information related to this proxy